Engineering anti‐GD2 monoclonal antibodies for cancer immunotherapy

@article{Ahmed2014EngineeringAM,
  title={Engineering anti‐GD2 monoclonal antibodies for cancer immunotherapy},
  author={Mahiuddin Ahmed and N. Cheung},
  journal={FEBS Letters},
  year={2014},
  volume={588}
}
Ganglioside GD2 is highly expressed on neuroectoderm‐derived tumors and sarcomas, including neuroblastoma, retinoblastoma, melanoma, small cell lung cancer, brain tumors, osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma in children and adolescents, as well as liposarcoma, fibrosarcoma, leiomyosarcoma and other soft tissue sarcomas in adults. Since GD2 expression in normal tissues is restricted to the brain, which is inaccessible to circulating antibodies, and in selected peripheral nerves and… Expand
GD2-targeted immunotherapy and radioimmunotherapy.
Disialoganglioside GD2 as a therapeutic target for human diseases
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
Targets and Antibody Formats for Immunotherapy of Neuroblastoma
  • Jeong A Park, N. Cheung
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2020
Primary Bone Tumors: Challenges and Opportunities for CAR‐T Therapies
Cancer-Associated Glycosphingolipids as Tumor Markers and Targets for Cancer Immunotherapy
Novel payloads for immunotoxin-based treatment of neuroblastoma
Anti-GD2 immunotherapy for neuroblastoma
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 125 REFERENCES
Anti-GD2 antibody therapy for GD2-expressing tumors.
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
  • N. Cheung, H. Lazarus, +7 authors N. Berger
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1987
Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.
  • R. Irie, D. Morton
  • Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1986
Disialoganglioside Directed Immunotherapy of Neuroblastoma
In vitro and in vivo antitumor activity of liposomal fenretinide targeted to human neuroblastoma
Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model
...
1
2
3
4
5
...